Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite
Michael Platten,1,3*
Peggy P. Ho,1*
Sawsan Youssef,1
Paulo Fontoura,1,4
Hideki Garren,1,5
Eun Mi Hur,1
Rohit Gupta,1
Lowen Y. Lee,1
Brian A. Kidd,1,6
William H. Robinson,1,6
Raymond A. Sobel,2
Michael L. Selley,7
Lawrence Steinman1
Abstract:
Local catabolism of the amino acid tryptophan (Trp) by indoleamine2,3-dioxygenase (IDO) is considered an important mechanism ofregulating T cell immunity. We show that IDO transcription wasincreased when myelin-specific T cells were stimulated withtolerogenic altered self-peptides. Catabolites of Trp suppressedproliferation of myelin-specific T cells and inhibited productionof proinflammatory T helper1 (TH1) cytokines. N-(3,4,-Dimethoxycinnamoyl)anthranilic acid (3,4-DAA), an orally active synthetic derivativeof the Trp metabolite anthranilic acid, reversed paralysis inmice with experimental autoimmune encephalomyelitis, a modelof multiple sclerosis (MS). Trp catabolites and their derivativesoffer a new strategy for treating TH1-mediated autoimmune diseasessuch as MS.
1 Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305, USA. 2 Department of Pathology (Neuropathology), Stanford University, Stanford, CA 94305, USA. 3 Department of General Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany. 4 Department of Immunology, Faculty of Medical Sciences, New University of Lisbon, 1169056 Lisbon, Portugal. 5 Bayhill Therapeutics Inc., Palo Alto, CA 94303, USA. 6 Geriatrics Research and Education Clinical Center (GRECC), Veterans Affairs Health System, Palo Alto, CA 94304, USA. 7 Angiogen Pharmaceuticals Pty. Ltd., Sydney, NSW 2000, Australia.
* These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail: steinman{at}stanford.edu (L.S.), michael.platten{at}uni-tuebingen.de (M.P.)
The editors suggest the following Related Resources on Science sites:
The roles of aryl hydrocarbon receptor in immune responses.
N. T. Nguyen, H. Hanieh, T. Nakahama, and T. Kishimoto (2013)
Int. Immunol.
25, 335-343
|Abstract »|Full Text »|PDF »
The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice.
L. Zhang, O. Ovchinnikova, A. Jonsson, A. M. Lundberg, M. Berg, G. K. Hansson, and D. F. J. Ketelhuth (2012)
Eur. Heart J.
33, 2025-2034
|Abstract »|Full Text »|PDF »
L-Tryptophan-Kynurenine Pathway Metabolites Regulate Type I IFNs of Acute Viral Myocarditis in Mice.
M. Hoshi, K. Matsumoto, H. Ito, H. Ohtaki, Y. Arioka, Y. Osawa, Y. Yamamoto, H. Matsunami, A. Hara, M. Seishima, et al. (2012)
J. Immunol.
188, 3980-3987
|Abstract »|Full Text »|PDF »
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.
R. B. Sorensen, S. R. Hadrup, I. M. Svane, M. C. Hjortso, P. thor Straten, and M. H. Andersen (2011)
Blood
117, 2200-2210
|Abstract »|Full Text »|PDF »
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism.
N. T. Nguyen, A. Kimura, T. Nakahama, I. Chinen, K. Masuda, K. Nohara, Y. Fujii-Kuriyama, and T. Kishimoto (2010)
PNAS
107, 19961-19966
|Abstract »|Full Text »|PDF »
IDO Upregulates Regulatory T Cells via Tryptophan Catabolite and Suppresses Encephalitogenic T Cell Responses in Experimental Autoimmune Encephalomyelitis.
Y. Yan, G.-X. Zhang, B. Gran, F. Fallarino, S. Yu, H. Li, M. L. Cullimore, A. Rostami, and H. Xu (2010)
J. Immunol.
185, 5953-5961
|Abstract »|Full Text »|PDF »
The Absence of IDO Upregulates Type I IFN Production, Resulting in Suppression of Viral Replication in the Retrovirus-Infected Mouse.
M. Hoshi, K. Saito, A. Hara, A. Taguchi, H. Ohtaki, R. Tanaka, H. Fujigaki, Y. Osawa, M. Takemura, H. Matsunami, et al. (2010)
J. Immunol.
185, 3305-3312
|Abstract »|Full Text »|PDF »
Insights into Therapy: Tryptophan Oxidation and HIV Infection.
M. F. Murray (2010)
Science Translational Medicine
2, 32ps23
|Full Text »|PDF »
Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease.
D. Favre, J. Mold, P. W. Hunt, B. Kanwar, P. Loke, L. Seu, J. D. Barbour, M. M. Lowe, A. Jayawardene, F. Aweeka, et al. (2010)
Science Translational Medicine
2, 32ra36
|Abstract »|Full Text »|PDF »
Expression analysis of novel striatal-enriched genes in Huntington disease.
G. Mazarei, S. J. Neal, K. Becanovic, R. Luthi-Carter, E. M. Simpson, and B. R. Leavitt (2010)
Hum. Mol. Genet.
19, 609-622
|Abstract »|Full Text »|PDF »
What have we learnt from targeted anti-TNF therapy?.
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.
L. K. Jasperson, C. Bucher, A. Panoskaltsis-Mortari, A. L. Mellor, D. H. Munn, and B. R. Blazar (2009)
Blood
114, 5062-5070
|Abstract »|Full Text »|PDF »
IDO Mediates TLR9-Driven Protection from Experimental Autoimmune Diabetes.
F. Fallarino, C. Volpi, T. Zelante, C. Vacca, M. Calvitti, M. C. Fioretti, P. Puccetti, L. Romani, and U. Grohmann (2009)
J. Immunol.
183, 6303-6312
|Abstract »|Full Text »|PDF »
Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.
F. Fallarino, G. Luca, M. Calvitti, F. Mancuso, C. Nastruzzi, M. C. Fioretti, U. Grohmann, E. Becchetti, A. Burgevin, R. Kratzer, et al. (2009)
J. Exp. Med.
206, 2511-2526
|Abstract »|Full Text »|PDF »
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
J. C. Schefold, J.-P. Zeden, C. Fotopoulou, S. von Haehling, R. Pschowski, D. Hasper, H.-D. Volk, C. Schuett, and P. Reinke (2009)
Nephrol. Dial. Transplant.
24, 1901-1908
|Abstract »|Full Text »|PDF »
The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation.
W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar (2008)
J. Immunol.
181, 5396-5404
|Abstract »|Full Text »|PDF »
Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus through indoleamine 2,3-dioxygenase in a murine model.
A. Saito, N. Motomura, K. Kakimi, K. Narui, N. Noguchi, M. Sasatsu, K. Kubo, Y. Koezuka, D. Takai, S. Ueha, et al. (2008)
J. Thorac. Cardiovasc. Surg.
136, 159-167
|Abstract »|Full Text »|PDF »
Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation.
H. Xu, T. B. Oriss, M. Fei, A. C. Henry, B. N. Melgert, L. Chen, A. L. Mellor, D. H. Munn, C. G. Irvin, P. Ray, et al. (2008)
PNAS
105, 6690-6695
|Abstract »|Full Text »|PDF »
IL-17 and Therapeutic Kynurenines in Pathogenic Inflammation to Fungi.
L. Romani, T. Zelante, A. De Luca, F. Fallarino, and P. Puccetti (2008)
J. Immunol.
180, 5157-5162
|Abstract »|Full Text »|PDF »
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
T. Hayashi, J.-H. Mo, X. Gong, C. Rossetto, A. Jang, L. Beck, G. I. Elliott, I. Kufareva, R. Abagyan, D. H. Broide, et al. (2007)
PNAS
104, 18619-18624
|Abstract »|Full Text »|PDF »
Dendritic Cell Type Determines the Mechanism of Bystander Suppression by Adaptive T Regulatory Cells Specific for the Minor Antigen HA-1.
R. A. Derks, E. Jankowska-Gan, Q. Xu, and W. J. Burlingham (2007)
J. Immunol.
179, 3443-3451
|Abstract »|Full Text »|PDF »
The anti-allergic drug, N-(3',4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis.
J. J. Inglis, G. Criado, M. Andrews, M. Feldmann, R. O. Williams, and M. L. Selley (2007)
Rheumatology
46, 1428-1432
|Abstract »|Full Text »|PDF »
Transient Upregulation of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Human Chorionic Gonadotropin Downregulates Autoimmune Diabetes.
A. Ueno, S. Cho, L. Cheng, J. Wang, S. Hou, H. Nakano, P. Santamaria, and Y. Yang (2007)
Diabetes
56, 1686-1693
|Abstract »|Full Text »|PDF »
Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C Virus Infection.
E. Larrea, J. I. Riezu-Boj, L. Gil-Guerrero, N. Casares, R. Aldabe, P. Sarobe, M. P. Civeira, J. L. Heeney, C. Rollier, B. Verstrepen, et al. (2007)
J. Virol.
81, 3662-3666
|Abstract »|Full Text »|PDF »
IL-8 and IDO Expression by Human Gingival Fibroblasts via TLRs.
R. Mahanonda, N. Sa-Ard-Iam, P. Montreekachon, A. Pimkhaokham, K. Yongvanichit, M. M. Fukuda, and S. Pichyangkul (2007)
J. Immunol.
178, 1151-1157
|Abstract »|Full Text »|PDF »
Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase.
F. Forouhar, J. L. R. Anderson, C. G. Mowat, S. M. Vorobiev, A. Hussain, M. Abashidze, C. Bruckmann, S. J. Thackray, J. Seetharaman, T. Tucker, et al. (2007)
PNAS
104, 473-478
|Abstract »|Full Text »|PDF »
The value of animal models for drug development in multiple sclerosis.
M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger (2006)
Brain
129, 1940-1952
|Abstract »|Full Text »|PDF »
Kynurenine Pathway Enzymes in Dendritic Cells Initiate Tolerogenesis in the Absence of Functional IDO.
M. L. Belladonna, U. Grohmann, P. Guidetti, C. Volpi, R. Bianchi, M. C. Fioretti, R. Schwarcz, F. Fallarino, and P. Puccetti (2006)
J. Immunol.
177, 130-137
|Abstract »|Full Text »|PDF »
The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor {zeta}-Chain and Induce a Regulatory Phenotype in Naive T Cells..
F. Fallarino, U. Grohmann, S. You, B. C. McGrath, D. R. Cavener, C. Vacca, C. Orabona, R. Bianchi, M. L. Belladonna, C. Volpi, et al. (2006)
J. Immunol.
176, 6752-6761
|Abstract »|Full Text »|PDF »